Express Scripts Holding Co (ESRX)

64.01
0.10 0.16
NASDAQ : Health Care
Prev Close 64.11
Open 64.01
Day Low/High 63.89 / 64.79
52 Wk Low/High 65.55 / 94.22
Volume 3.76M
Avg Volume 4.21M
Exchange NASDAQ
Shares Outstanding 600.31M
Market Cap 38.43B
EPS 5.40
P/E Ratio 11.88
Div & Yield N.A. (N.A)

Latest News

Politicians Question EpiPen Competitor's High Pricetag

Politicians Question EpiPen Competitor's High Pricetag

Chuck Grassley is hammering the privately held drug company on its $4,500 EpiPen competitor.

Market Recon: President Trump's Speech Will Dominate Trading

Market Recon: President Trump's Speech Will Dominate Trading

I believe this president goes full Trumpian tonight, in a style that he has made all his own.

Here's Why AmerisourceBergen Is Up 16% This Year

Here's Why AmerisourceBergen Is Up 16% This Year

The pharmaceutical distributor is finally turning around.

What We Need to Know: Express Scripts Q4 Earnings

What We Need to Know: Express Scripts Q4 Earnings

It used the earning's call to pass much of the blame for high drug prices onto pharmaceutical companies.

Express Scripts: Rx For Earnings Growth

Express Scripts: Rx For Earnings Growth

The country's largest pharmacy benefits manager is enjoying tailwinds after reporting a big jump in year-over-year profits.

Express Scripts Officials Use Earnings Call to Blame Pharma for Drug Pricing

Express Scripts Officials Use Earnings Call to Blame Pharma for Drug Pricing

The pharmacy benefit manager shifted blame for drug pricing back to pharma companies.

How Kaleo Pharma Prices Its EpiPen Competitor

How Kaleo Pharma Prices Its EpiPen Competitor

Kaleo's EpiPen compeitor the Auvi-Q was released today.

Mylan Shares Unchanged as Kaleo Releases EpiPen Competitor

Mylan Shares Unchanged as Kaleo Releases EpiPen Competitor

The Auvi-Q was released Feb. 14, but it's unclear whether patients will break up with their current option, EpiPen, for something new.

Bearish Bets: A PBM, a Regional Airline and Other Stocks That Look Good Short

BLL, OPK, ESRX, SKYW and DLA all were recently downgraded by TheStreet's Quant Ratings.

Barclays, Banco Santander, Amgen, UnitedHealth Group: 'Mad Money' Lightning Round

Barclays, Banco Santander, Amgen, UnitedHealth Group: 'Mad Money' Lightning Round

Jim Cramer likes European banks, plus Banco Santander, and New York Community Bancorp, too.

Analyzing Risks Posed by a Possible Trump Correction: Cramer's 'Mad Money' Recap (Tuesday 2/7/17)

Analyzing Risks Posed by a Possible Trump Correction: Cramer's 'Mad Money' Recap (Tuesday 2/7/17)

Jim Cramer takes a closer look at the risks: Don't measure 'Trump per share,' measure actual earnings per share.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AG, AMZN, CBPX, CTLT, FSM, GOLD, LADR, OHI Downgrades: ESRX, GCO, NXPI, OPB, PIP, RDY, TM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

The S&P 500 Companies With the Most Diverse Boards

The S&P 500 Companies With the Most Diverse Boards

The most ethnically and gender diverse boards may surprise you.

Express Scripts Fights Back Against Irresponsible Drug Pricing; Holds U.S. Drug Spending Increase To 3.8 Percent In 2016

Express Scripts Fights Back Against Irresponsible Drug Pricing; Holds U.S. Drug Spending Increase To 3.8 Percent In 2016

- Patients' share of cost for prescription drugs declined for the second consecutive year

Express Scripts Falls on Attack From Andrew Left

Express Scripts Falls on Attack From Andrew Left

The comparison to the New York mob boss was only the beginning of Citron Research's inflammatory comments

Real Money's Stephen Guilfoyle on the Stock Market's Danger Signs

Real Money's Stephen Guilfoyle on the Stock Market's Danger Signs

Real Money contributor Stephen Guilfoyle sees some reasons for caution in stock trading right now.

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

It's unclear how much of the hefty $4,500 price pharmacy benefit managers or insurers will agree to pay to keep Auvi-Q free for most patients.

Aetna May Not Be Ready to Scrap Its Scuttled $37 Billion Humana Tie-up

Aetna May Not Be Ready to Scrap Its Scuttled $37 Billion Humana Tie-up

The combination of the insurance giants was found to be a threat to competition.

Insulin Drug Offers Hope for MannKind

Insulin Drug Offers Hope for MannKind

The stock has taken a beating, but users of Afrezza are loyal to the drug.

See How Express Scripts Holding Ranks Among Analysts' Top Picks With Strong Buyback Activity

See How Express Scripts Holding Ranks Among Analysts' Top Picks With Strong Buyback Activity

A study of analyst recommendations at the major brokerages shows that Express Scripts Holding Co is the #84 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Doug Kass' Top Pick for 2017: Short QQQ

Doug Kass' Top Pick for 2017: Short QQQ

Kass' trade of the year for 2017 is to short the PowerShares QQQ Trust ETF.